ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 490,28
0,51%
Dow Jones
42 635,20
0,00%
DAX
20 317,10
0,00%
Brent Oil
76,735
0,98%
Bitcoin
93 122,36
-2,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Milestone Pharmaceuticals Inc (MIST)

  7. Milestone Pharmaceuticals Inc (MIST) Actualités

MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MIST
DateHeureSourceTitreSymboleSociété
07/01/202514h00GlobeNewswire Inc.Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MISTMilestone Pharmaceuticals Inc
25/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MISTMilestone Pharmaceuticals Inc
12/11/202422h38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MISTMilestone Pharmaceuticals Inc
12/11/202422h36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MISTMilestone Pharmaceuticals Inc
12/11/202415h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
12/11/202413h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/08/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
17/07/202422h16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MISTMilestone Pharmaceuticals Inc
17/07/202400h06Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202422h41Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202422h38Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MISTMilestone Pharmaceuticals Inc
15/07/202422h34Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202414h00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202422h52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202413h00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202422h37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
15/02/202402h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202314h54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313h57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202313h00PR Newswire (US)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h57PR Newswire (US)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202316h00PR Newswire (Canada)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
09/11/202322h43Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202313h00PR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202313h00PR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
27/09/202313h00PR Newswire (Canada)Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
05/09/202313h00PR Newswire (US)Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
10/08/202313h35PR Newswire (US)Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
20/06/202313h00PR Newswire (Canada)Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The LancetNASDAQ:MISTMilestone Pharmaceuticals Inc
09/06/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MISTMilestone Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIST

Dernières Valeurs Consultées

COIN
ETHUSD
Ethereum
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
LR
Legrand
EU
PX4
SBF 120
EU
RI
Pernod Ricard
NASDAQ
NVDA
NVIDIA
EU
EN
Bouygues
EU
PX1
CAC 40
EU
ACA
Credit Agricole
EU
RNO
Renault
NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés